Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;13(4):321-6.
doi: 10.1007/s10194-012-0416-y. Epub 2012 Jan 26.

Metabolic syndrome and insulin resistance in migraine

Affiliations

Metabolic syndrome and insulin resistance in migraine

Sanjeev K Bhoi et al. J Headache Pain. 2012 Jun.

Abstract

Metabolic syndrome is associated with migraine but there is no study comparing the characteristics of migraine with and without metabolic syndrome from Southeast Asia. This study was therefore undertaken to compare the clinical characteristics of migraine in patients with and without metabolic syndrome and insulin resistance. 135 consecutive patients with migraine diagnosed on the basis of International Headache Society criteria were subjected to clinical evaluation as per fixed protocol. Headache severity, frequency and functional disability were recorded. Metabolic syndrome was diagnosed as per National Cholesterol Education Programme: Adult Treatment Panel III and International Diabetic Federation criteria. Insulin resistance was calculated by homeostases model assessment. Their age ranged between 14 and 61 years and 108 were females. Metabolic syndrome was present in 31.9% patients and only 13 were obese. Insulin resistance was present in 11.1%. Metabolic syndrome was correlated with age, gender, number of triggers, years of headache and duration of migraine attacks. Insulin resistance correlated with duration of migraine attacks. From this study, it can be concluded that metabolic syndrome was present in 31.9% of the migraineurs which was mainly in elderly who had longer duration of headache and multiple triggers.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Robbins MS, Lipton RB. The epidemiology of primary headache disorder. Semin Neurol. 2010;30:107–119. doi: 10.1055/s-0030-1249220. - DOI - PubMed
    1. Brennum J, Brinck T, Schriver L, et al. Sumatriptan has no clinically relevant effect in the treatment of episodic tension type headache. Eur J Neurol. 1996;3:23–28. doi: 10.1111/j.1468-1331.1996.tb00184.x. - DOI
    1. Stang PE, Carson AP, Rose KM, et al. Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology. 2005;64:1573–1577. doi: 10.1212/01.WNL.0000158326.31368.04. - DOI - PubMed
    1. Lipton RB, Stewart WF, Cady R, et al. Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache. 2000;40:783–791. doi: 10.1046/j.1526-4610.2000.00143.x. - DOI - PubMed
    1. Lj Stovner, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210. doi: 10.1111/j.1468-2982.2007.01288.x. - DOI - PubMed